66.

Bickelman C, Ferries L, Eaton RP. Impotence related to anabolic steroid use

in a body builder. Response to clomiphene citrate. West J Med 1995;162:

158

–

67.

Menon DK. Successful treatment of anabolic steroid-induced azoospermia

with human chorionic gonadotropin and human menopausal gonado-

tropin. Fertil Steril 2003;79(Suppl 3):1659

–

68.

Tan RS, Vasudevan D. Use of clomiphene citrate to reverse premature

andropause secondary to steroid abuse. Fertil Steril 2003;79:203

–

69.

Weinstein RL, Reitz RE. Pituitary-testicular responsiveness in male hypogo-

nadotropic hypogonadism. J Clin Invest 1974;53:408

–

70.

Moskovic DJ, Katz DJ, Akhavan A, Park K, Mulhall JP. Clomiphene citrate is

safe and effective for long-term management of hypogonadism. BJU Int

2012;110:1524

–

71.

de Luis DA, Aller R, Cu

ellar LA, Terroba C, Romero E. [Anabolic steroids and

gynecomastia. Review of the literature]. An Med Interna 2001;18:489

–

72.

Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med 2007;357:

1229

–

73.

Ferrando J, Grimalt R, Alsina M, Bulla F, Manasievska E. Unilateral gyneco-

mastia induced by treatment with 1 mg of oral

nasteride. Arch Dermatol

2002;138:543

–

74.

Green L, Wysowski DK, Fourcroy JL. Gynecomastia and breast cancer dur-

ing

nasteride therapy. N Engl J Med 1996;335:823

75.

Lee SC, Ellis RJ. Male breast cancer during

nasteride therapy. J Natl Cancer

Inst 2004;96:338

–

76.

Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side ef-

fects of 5

-reductase inhibitors therapy: persistent diminished libido and

erectile dysfunction and depression in a subset of patients. J Sex Med

2011;8:872

–

77.

Jameel JKA, Kneeshaw PJ, Rao VSR, Drew PJ. Gynaecomastia and the plant

product

‘‘

Tribulis terrestris

’’

. Breast 2004;13:428

–

78.

Toorians AWFT, Bovee TFH, de Rooy J, Stolker LAAM, Hoogenboom RLAP.

Gynaecomastia linked to the intake of a herbal supplement forti

ed with

diethylstilbestrol. Food Addit Contam Part A Chem Anal Control 2010;

27:917

–

79.

Deepinder F, Braunstein GD. Drug-induced gynecomastia: an evidence-

based review. Expert Opin Drug Saf 2012;11:779

–

80.

Dickson G. Gynecomastia. Am Fam Physician 2012;85:716

–

81.

Hanavadi S, Banerjee D, Monypenny IJ, Mansel RE. The role of tamoxifen in

the management of gynaecomastia. Breast 2006;15:276

–

82.

Spano F, Ryan WG. Tamoxifen for gynecomastia induced by anabolic ste-

roids? N Engl J Med 1984;311:861

–

83.

Babigian A, Silverman RT. Management of gynecomastia due to use of

anabolic steroids in bodybuilders. Plast Reconstr Surg 2001;107:240

–

84.

Neild D. Gynaecomastia in bodybuilders. Br J Clin Pract 1995;49:172

85.

Boccardo F, Rubagotti A, Battaglia M, di Tonno P, Selvaggi FP, Conti G,

et al. Evaluation of tamoxifen and anastrozole in the prevention of gyneco-

mastia and breast pain induced by bicalutamide monotherapy of prostate

cancer. J Clin Oncol 2005;23:808

–

86.

Lawrence SE, Faught KA, Vethamuthu J, Lawson ML. Bene

cial effects of

raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J

Pediatr 2004;145:71

–

87.

Parker LN, Gray DR, Lai MK, Levin ER. Treatment of gynecomastia with

tamoxifen: a double-blind crossover study. Metabolism 1986;35:705

–

88.

Buvat J, Ardaens K, Lemaire A, Gauthier A, Gasnault JP, Buvat-Herbaut M.

Increased sperm count in 25 cases of idiopathic normogonadotropic

oligospermia following treatment with tamoxifen. Fertil Steril 1983;39:

700

–

89.

de la Torre Abril L, Ramada Benlloch F, S

anchez Ballester F, Ordo

Domínguez F, Ulises Juan Escudero J, Naval

on Verdejo P, et al. [Manage-

ment of male sterility in patients taking anabolic steroids]. Arch Esp Urol

2005;58:241

–

90.

Dony JM, Smals AG, Rolland R, Fauser BC, Thomas CM. Effect of lower

versus higher doses of tamoxifen on pituitary-gonadal function and sperm

indices in oligozoospermic men. Andrologia 1985;17:369

–

91.

Tsourdi E, Kourtis A, Farmakiotis D, Katsikis I, Salmas M, Panidis D. The ef-

fect of selective estrogen receptor modulator administration on the

hypothalamic-pituitary-testicular axis in men with idiopathic oligozoosper-

mia. Fertil Steril 2009;91:1427

–

92.

Veldhuis JD, Dufau ML. Estradiol modulates the pulsatile secretion of bio-

logically active luteinizing hormone in man. J Clin Invest 1987;80:631

–

93.

Vermeulen A, Comhaire F. Hormonal effects of an antiestrogen, tamox-

ifen, in normal and oligospermic men. Fertil Steril 1978;29:320

–

94.

Finkelstein JS, Lee H, Burnett-Bowie S-AM, Pallais JC, Yu EW, Borges LF,

et al. Gonadal steroids and body composition, strength, and sexual func-

tion in men. N Engl J Med 2013;369:1011

–

95.

Dohle GR, Smit M, Weber RFA. Androgens and male fertility. World J Urol

2003;21:341

–

96.

Lombardo F, Sgr

o P, Salacone P, Gilio B, Gandini L, Dondero F, et al. Andro-

gens and fertility. J Endocrinol Invest 2005;28:51

–

97.

Bagatell CJ, Bremner WJ. Androgens in men

—

uses and abuses. N Engl

J Med 1996;334:707

–

98.

Ko EY, Siddiqi K, Brannigan RE, Sabanegh ES Jr. Empirical medical therapy

for idiopathic male infertility: a survey of the American Urological Associa-

tion. J Urol 2012;187:973

–

99.

Basaria S. Androgen abuse in athletes: detection and consequences. J Clin

Endocrinol Metab 2010;95:1533

–

100.

Gazvani MR, Buckett W, Luckas MJ, Aird IA, Hipkin LJ, Lewis-Jones DI. Con-

servative management of azoospermia following steroid abuse. Hum

Reprod 1997;12:1706

–

101.

Knuth UA, Maniera H, Nieschlag E. Anabolic steroids and semen parame-

ters in bodybuilders. Fertil Steril 1989;52:1041

–

102.

Turek PJ, Williams RH, Gilbaugh JH 3rd, Lipshultz LI. The reversibility of

anabolic steroid-induced azoospermia. J Urol 1995;153:1628

–

103.

Grokett BH, Ahmad N, Warren DW. The effects of an anabolic steroid (ox-

androlone) on reproductive development in the male rat. Acta Endocrinol

(Copenh) 1992;126:173

–

104.

Hsieh T-C, Pastuszak AW, Hwang K, Lipshultz LI. Concomitant intramus-

cular human chorionic gonadotropin preserves spermatogenesis in men

undergoing testosterone replacement therapy. J Urol 2013;189:647

–

105.

Vicari E, Mongioì A, Calogero AE, Moncada ML, Sidoti G, Polosa P, et al.

Therapy with human chorionic gonadotrophin alone induces spermato-

genesis in men with isolated hypogonadotrophic hypogonadism

—

long-

term follow-up. Int J Androl 1992;15:320

–

106.

Kim S-O, Ryu KH, Hwang IS, Jung SI, Oh KJ, Park K. Penile growth in

response to human chorionic gonadotropin (hCG) treatment in patients

with idiopathic hypogonadotrophic hypogonadism. Chonnam Med J

2011;47:39

–

107.

Gardner FH, Nathan DG, Piomelli S, Cummins JF. The erythrocythaemic

effects of androgen. Br J Haematol 1968;14:611

–

108.

Gooren LJ. Androgens and male aging: current evidence of safety and

cacy. Asian J Androl 2010;12:136

–

109.

Stergiopoulos K, Brennan JJ, Mathews R, Setaro JF, Kort S. Anabolic

steroids, acute myocardial infarction and polycythemia: a case report and

review of the literature. Vasc Health Risk Manag 2008;4:1475

–

VOL. 101 NO. 5 / MAY 2014

1279

Fertility and Sterility®